Use of Stereotactic Radioablation Therapy as a Bailout Therapy for Refractory Ventricular Tachycardia in a Patient with a No-entry Left Ventricle

DOI: 10.19102/icrm.2021.120902

DURSUN ARAS, MD,¹ HUSEYIN FURKAN OZTURK, MD,² ELIF OZDEMIR, MD,³ UMIT KERVAN, MD,⁴ MERYEM KARA, MD,¹ SERKAN CAY, MD,¹ NAZIM COSKUN, MD,³ FIRAT OZCAN, MD,¹ AHMET KORKMAZ, MD,¹ OZCAN OZEKE, MD,¹ SERKAN TOPALOGLU, MD,¹ and YILMAZ TEZCAN, MD²

¹Department of Cardiology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey

²Department of Radiation Oncology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey

³Department of Nuclear Medicine, University of Health Sciences, Ankara City Hospital, Ankara, Turkey

⁴Department of Cardiovascular Surgery, University of Health Sciences, Ankara City Hospital, Ankara, Turkey

Download PDF

Follow Us >> Tweet

ABSTRACT. In patients with mechanical aortic and mitral valves and left ventricular (LV) tachycardia (VT), catheter ablation is technically challenging due to the limited access to the LV. Promising new alternatives to radiofrequency ablation include pulsed-field electroporation, percutaneous or surgical sympathetic neuromodulation, and noninvasive stereotactic radioablation therapy (SBRT). We herein describe the effect of SBRT as a bailout therapy on the management of a challenging VT case in the presence of double left-sided mechanical valves.

KEYWORDS. Mechanical aortic and mitral valve, no-entry left ventricle, refractory ventricular tachycardia, SBRT, stereotactic radioablation therapy.

The authors report no conflicts of interest for the published content.
Manuscript received December 6, 2020. Final version accepted January 25, 2021.
Address correspondence to: Ozcan Ozeke, MD, Sağlık Bilimleri Üniversitesi, Ankara Şehir Hastanesi, Kardiyoloji Klinigi, Bilkent, Ankara 06800, Turkey. Email: ozcanozeke@gmail.com.

Introduction

In patients with mechanical aortic and mitral valves and left ventricular (LV) tachycardia (VT), catheter ablation is technically challenging due to the limited access to the LV. Several operators have reported on the application of non-conventional techniques for VT ablation, including transventricular septal puncture, transmechanical valve, transcoronary venous, and transapical approaches.^1–5 Promising alternatives to radiofrequency ablation include percutaneous or surgical sympathetic neuromodulation, alcohol ablation from the coronary arterial or venous system, direct current or pulsed-field electroporation, and noninvasive stereotactic radioablation therapy (SBRT) in critically ill patients.^6–9 We herein describe the effect of SBRT as a bailout therapy on the management of a challenging VT case with two mechanical valve prostheses in aortic and mitral positions.²

Case presentation

A 58-year-old man with two mechanical valves in mitral and aortic positions was referred after multiple appropriate implantable cardioverter-defibrillator shocks despite oral amiodarone and mexiletine therapies. He had nonischemic, valvular, dilated cardiomyopathy with an LV ejection fraction of 15% and had undergone implantation of a cardiac resynchronization therapy (CRT) device 10 years prior. His documented monomorphic VT suggested a lateral mid-LV exit (Figure 1). Due to his previous double valve surgery, we planned and performed an epicardial VT ablation via a lateral thoracotomy (Figure 2A). Electroanatomic mappings (CARTO^® 3; Biosense Webster, Diamond Bar, CA, USA) showed scar regions containing local abnormal ventricular activities (LAVAs) in the inferolateral wall of the LV (Figure 2B). Despite epicardial LAVA ablation, after five months, recurrent VT episodes with similar exit sites from previously delineated scar regions recurred under amiodarone, mexiletine, and sotalol therapies. We also transiently switched off the CRT device to exclude the possible lead-related VT, as there are some controversial data concerning the proarrhythmic or antiarrhythmic potential of CRT therapy.¹⁰ As all available cardiologic therapeutic strategies failed to free the patient from VT recurrence, we decided to implement SBRT as a therapy of last resort after discussions in our group and with the patient and his relatives. In the next step, positron-emission tomography-computed tomography (PET-CT) showed hypometabolic scar areas in the inferolateral walls corresponding with previous electroanatomic maps (Figure 2C). A four-dimensional (4D) CT scan (General Electric Healthcare, Milwaukee, WI, USA) with 10 respiratory phases was performed for radiotherapy planning using an alpha cradle and a chest board for immobilization after an eight-hour fast. After transferring the CT images to the radiotherapy planning system (Eclipse™; Varian Medical Systems, Palo Alto, CA, USA), an average-phase CT (avgCT) was created to evaluate cardiac and respiratory movements. After the fusion of PET-CT and avgCT images using the RT planning software (Varian Medical Systems) (Figures 2C–2F), an inferolateral hypometabolic scar region with the guidance of electroanatomic mapping was created as the internal gross target volume (IGTV). To overcome any uncertainties during positioning, motion, and therapy, a 5-mm safety margin was added to the IGTV for obtaining the final planned target volume (PTV) (Figure 3). Before treatment delivery, re-imaging with cone-beam CT was performed for comparison and alignment of images with simulation images. All treatment procedures were handled by a team of electrophysiologists, radiation oncologists, nuclear medicine specialists, and radiation physicists. Radiotherapy was given using a linear accelerator device (TrueBeam^®; Varian Medical). A total dose of 25 Gy was delivered in a single fraction to the PTV in 7.5 minutes to be targeted by at least 95% of the given dose. Despite rare hemodynamically stable slow VT episodes responding to antitachycardia pacing, a significant reduction in VT episodes was observed within the first eight months after radioablation therapy (Figure 2G). No abnormal device parameters nor acute or chronic adverse effects were detected at 10 months. At present, the patient is being followed up with at the outpatient clinic.

Discussion

The growing burden of ventricular arrhythmias and their significant morbidity and mortality rates demand new effective therapeutic approaches based on a given patient’s triggers, comorbidities, and underlying pathology. Mechanical prosthetic aortic and mitral valves impede either a retrograde aortic or transseptal approach to the LV endocardium. SBRT, delivered in a single dose of 25 Gy, may serve as an alternative or palliative therapy for otherwise untreatable patients with refractory VT and electrical storm who are otherwise ineligible for catheter ablation,^6,11–13 potentially keeping ventricular arrhythmias quiescent while awaiting heart transplantation,¹⁴ as was done in the current case. Because of its high precision and target conformity, it can deliver a high dose of radiation to a specific area in tissue without significantly affecting the nearby tissues.^15–18 Indeed, the radiobiology of this treatment when applied to noncancer myocytes is limited, but endothelial vacuolization is a well-described effect of radiation.¹⁹ There have been studies that have investigated single-fraction whole-heart irradiation in animal models, and these demonstrated dose-dependent myocardial degeneration and fibrosis progressing from the epicardial tissue to full transmurality in the months after irradiation at doses of 20 Gy and higher.^20,21 Histopathologic findings in the human myocardium after SBRT for recalcitrant VT have also provided radiobiological mechanisms of acute cellular injury during SBRT for VT, which may have an antiarrhythmic effect before the onset of fibrosis.²² These data suggest that SBRT can also be used as a relatively acute antiarrhythmic palliation in patients with electrical storm.²¹ Nonetheless, the optimal dose regimen has yet to be elucidated, and the long-term efficacy and toxicity of SBRT remain unsettled. Before more data on efficacy and safety are obtained, it could be offered as a “bailout” procedure after failed endo- and/or epicardial catheter ablation.^12,23 The current case suggested that the noninvasive SBRT was applicable as a potential salvage treatment option for patients with double mechanical valves with dosage at 25 Gy providing the safest short-term profile. A recent systematic literature review summarized that VT was targeted with reduction in the number of episodes beyond 85% during follow-up, with an encouraging short-term safety profile.²⁴ Nevertheless, the same analysis revealed significant heterogeneity in the available study designs, limiting the clinical evidence on the efficacy and safety of SBRT.²⁴ Moving forward, randomized clinical trials will be essential to establish the safety, efficacy, and comparative effectiveness of this new and promising modality.²³

References

1. Aras D, Topaloglu S, Ozeke O, Ozcan F, Cay S, Golbasi Z. Percutaneous interventricular septal access guided by subcostal echocardiography and fluoroscopy for ventricular tachycardia ablation in a patient with aortic and mitral mechanical valves. J Innov Card Rhythm Manag. 2019;10(7):3719–3721. [CrossRef] [PubMed]
2. Ozeke O, Cay S, Ozcan F, Topaloglu S, Aras D. The reentry circuit and route in no entry left ventricle situations for ventricular tachycardia ablations. Pacing Clin Electrophysiol. 2018;41(6):678. [CrossRef] [PubMed]
3. Vurgun VK, Altin AT, Kilickap M, Candemir B, Akyurek O. Percutaneous transapical approach and transcatheter closure for ventricular tachycardia ablation. Pacing Clin Electrophysiol. 2018;41(6):680. [CrossRef] [PubMed]
4. Yorgun H, Canpolat U, Nof E, et al. Transapical left ventricular access for ventricular tachycardia ablation in patients with mechanical aortic and mitral valve prosthesis. Circ Arrhythm Electrophysiol. 2020;13(10):e008893. [CrossRef] [PubMed]
5. Santangeli P, Hyman MC, Muser D, Callans DJ, Shivkumar K, Marchlinski FE. Outcomes of percutaneous trans-right atrial access to the left ventricle for catheter ablation of ventricular tachycardia in patients with mechanical aortic and mitral valves. JAMA Cardiol. 2020;6(3):1–6. [CrossRef] [PubMed]
6. Robinson CG, Samson PP, Moore KMS, et al. Phase I/II trial of electrophysiology-guided noninvasive cardiac radioablation for ventricular tachycardia. Circulation. 2019;139(3):313–321. [CrossRef] [PubMed]
7. Kim EJ, Davogustto G, Stevenson WG, John RM. Non-invasive cardiac radiation for ablation of ventricular tachycardia: a new therapeutic paradigm in electrophysiology. Arrhythm Electrophysiol Rev. 2018;7(1):8–10. [CrossRef] [PubMed]
8. Cuculich PS, Schill MR, Kashani R, et al. Noninvasive cardiac radiation for ablation of ventricular tachycardia. N Engl J Med. 2017;377(24):2325–2336. [CrossRef] [PubMed]
9. Aksu T, Guler TE, Bozyel S, Yalin K, Gopinathannair R. Potential therapeutic effects of electrogram-guided cardioneuroablation in long QT syndrome: case series. J Interv Card Electrophysiol. 2020 Jul 23. [Epub ahead of print]. [CrossRef] [PubMed]
10. Kawamura M, Arai S, Yoshikawa K, et al. Association left ventricular lead and ventricular arrhythmias after upgrade to cardiac resynchronization therapy in patients with implantable cardioverter defibrillators. Clin Cardiol. 2019;42(7):670–677. [CrossRef] [PubMed]
11. Lloyd MS, Wight J, Schneider F, et al. Clinical experience of stereotactic body radiation for refractory ventricular tachycardia in advanced heart failure patients. Heart Rhythm. 2020;17(3):415–422. [CrossRef] [PubMed]
12. Jumeau R, Ozsahin M, Schwitter J, et al. Rescue procedure for an electrical storm using robotic non-invasive cardiac radio-ablation. Radiother Oncol. 2018;128(2):189–191. [CrossRef] [PubMed]
13. Jumeau R, Ozsahin M, Schwitter J, et al. Stereotactic radiotherapy for the management of refractory ventricular tachycardia: promise and future directions. Front Cardiovasc Med. 2020;7:108. [CrossRef] [PubMed]
14. Lyle M, Lloyd M, Higgins K, et al. Stereotactic body radiation for refractory ventricular tachycardia in patients with left ventricular assist devices. J Heart Lung Transplant. 2020;39(4):S349. [CrossRef]
15. Refaat MM, Zakka P, Youssef B, Zeidan YH, Geara F, Al-Ahmad A. Noninvasive cardioablation. Card Electrophysiol Clin. 2019;11(3):481–485. [CrossRef] [PubMed]
16. Weidlich GA, Hacker F, Bellezza D, Maguire P, Gardner EA. Ventricular tachycardia: a treatment comparison study of the cyberknife with conventional linear accelerators. Cureus. 2018;10(10):e3445. [CrossRef] [PubMed]
17. John RM, Shinohara ET, Price M, Stevenson WG. Radiotherapy for ablation of ventricular tachycardia: assessing collateral dosing. Comput Biol Med. 2018;102:376–380. [CrossRef] [PubMed]
18. Kelsey KL, Kubicek LN, Bacon NJ, Torres T, Robertson SA. Neuromuscular blockade and inspiratory breath hold during stereotactic body radiation therapy for treatment of heart base tumors in four dogs. J Am Vet Med Assoc. 2017;250(2):199–204. [CrossRef] [PubMed]
19. Shim S, Lee JG, Bae CH, et al. Claudin-3 expression in radiation-exposed rat models: a potential marker for radiation-induced intestinal barrier failure. Biochem Biophys Res Commun. 2015;456(1):351–354. [CrossRef] [PubMed]
20. Kruse JJ, Zurcher C, Strootman EG, et al. Structural changes in the auricles of the rat heart after local ionizing irradiation. Radiother Oncol. 2001;58(3):303–311. [CrossRef] [PubMed]
21. Lauk S, Kiszel Z, Buschmann J, Trott KR. Radiation-induced heart disease in rats. Int J Radiat Oncol Biol Phys. 1985;11(4):801–808. [CrossRef] [PubMed]
22. Kiani S, Kutob L, Schneider F, Higgins KA, Lloyd MS. Histopathologic and ultrastructural findings in human myocardium after stereotactic body radiation therapy for recalcitrant ventricular tachycardia. Circ Arrhythm Electrophysiol. 2020;13(11):e008753. [CrossRef] [PubMed]
23. Neuwirth R, Cvek J, Knybel L, et al. Stereotactic radiosurgery for ablation of ventricular tachycardia. Europace. 2019;21(7):1088–1095. [CrossRef] [PubMed]
24. van der Ree MH, Blanck O, Limpens J, et al. Cardiac radioablation-A systematic review. Heart Rhythm. 2020;17(8):1381–1392. [CrossRef] [PubMed]